Novavax vaccine enters phase 3 trials in US, Mexico

The American biotech company Novavax began its clinical trials to determine the safety and efficacy of a Covid-19 vaccine candidate in the United States and Mexico, announced the US National Institutes of Health (NIH) on December 28.

The leading US immunologist Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH said, “The launch of this study — the fifth investigational COVID-19 vaccine candidate to be tested in a Phase 3 trial in the United States — demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines.”

It must also be noted that a similar Phase 3 trial for the same vaccine, called NVX-CoV2373, is also under way in the United Kingdom.

Photo Credit :